151. Comparing tau status determined via plasma pTau181, pTau231 and [
- Author
-
Cécile, Tissot, Joseph, Therriault, Peter, Kunach, Andréa, L Benedet, Tharick A, Pascoal, Nicholas J, Ashton, Thomas K, Karikari, Stijn, Servaes, Firoza Z, Lussier, Mira, Chamoun, Dana L, Tudorascu, Jenna, Stevenson, Nesrine, Rahmouni, Nina Margherita, Poltronetti, Vanessa, Pallen, Gleb, Bezgin, Min Su, Kang, Sulantha S, Mathotaarachchi, Yi-Ting, Wang, Jaime, Fernandez Arias, Pamela Cristina Lukasewicz, Ferreira, João Pedro, Ferrari-Souza, Eugeen, Vanmechelen, Kaj, Blennow, Henrik, Zetterberg, Serge, Gauthier, and Pedro, Rosa-Neto
- Subjects
Canada ,Amyloid beta-Peptides ,Alzheimer Disease ,Positron-Emission Tomography ,Humans ,Cognitive Dysfunction ,tau Proteins ,Biomarkers - Abstract
Tau in Alzheimer's disease (AD) is assessed via cerebrospinal fluid (CSF) and Positron emission tomography (PET). Novel methods to detect phosphorylated tau (pTau) in blood have been recently developed. We aim to investigate agreement of tau status as determined by [We assessed cognitively unimpaired young, cognitively unimpaired, mild cognitive impairment and AD individuals with [The threshold for positivity was 15.085 pg/mL for plasma pTau181 and 17.652 pg/mL for plasma pTau231. Most individuals had concordant statuses, however, 18% of plasma181/PET, 26% of plasma231/PET and 25% of the pTau231/pTau181 were discordant. Positivity to at least one biomarker was often accompanied by diagnosis of cognitive impairment, Aβ positivity, APOEε4 carriership, higher levels of [Plasma pTau181, pTau231 and [Moreover, this study was supported by Weston Brain Institute, Canadian Institute of Health Research and Fonds de Recherche du Québec.
- Published
- 2021